Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Distillery Therapeutics

Inhibiting PCSK9 for breast cancer metastasis

January 28, 2025 12:50 AM UTC

Inhibiting PCSK9, an enzyme that regulates cholesterol metabolism by degrading lipoprotein receptors, could decrease metastatic initiation and proliferation by stabilizing the lipoprotein receptor LRP1 on tumor cells, whose downstream signaling suppresses expression of metastasis-promoting genes.

Genome-wide association studies of breast cancer patients identified a common gain-of-function missense germline variant in PCSK9 (V474I) that, when homozygous, was associated with shorter overall survival, and conferred a 22% risk of distant metastatic relapse at 15 years, while heterozygous patients had a 2% risk. ...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article